Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaRichard R. Furman, Susan O’Brien, Jeff P. Sharman et al.|New England Journal of Medicine|2014Cited by 1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaJohn C. Byrd, Peter Hillmen, Jennifer R. Brown et al.|New England Journal of Medicine|2014Cited by 1.6k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaWyndham H. Wilson, Louis M. Staudt, André Goy et al.|Nature Medicine|2015Cited by 1.1k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Richard R. Furman, Bonnie K. Harrington et al.|New England Journal of Medicine|2015Cited by 890
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaTait D. Shanafelt, Martin S. Tallman, Xin V. Wang et al.|New England Journal of Medicine|2019Cited by 735